Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

$VKTXPress releaseMay 5, 2026, 7:05 AM ETRead the release

Viking Therapeutics announced it will present two posters on its VK2735 program at the European Congress on Obesity in May 2026. One poster will cover Phase 2 VENTURE-Oral trial data on weight loss and safety, while the second will detail the design of the ongoing Phase 3 VANQUISH-1 trial.

Key figures

Drug Name: VK2735
Phase Of Trial: Phase 2, Phase 3

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.